NCT07328074Not yet recruiting
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
Prospective Cohort Study of Electrocautery Resection Combined With Hyperthermic Intrathoracic Chemotherapy for Thymic Epithelial Tumors With Pleural Metastasis
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or recurrence. The study aims to: * Evaluate whether this combined treatment improves event-free survival in patients with pleural metastasis from thymic epithelial tumors * Assess the rates of grade ≥3 treatment-related adverse events * Examine how this treatment affects patients' quality of life Participants will: * Undergo extended thymectomy with electrocautery resection of pleural metastases * Receive two cycles of hyperthermic intrathoracic chemotherapy with cisplatin and doxorubicin at 42-43°C, 2-4 days apart * Complete quality of life questionnaires (EQ-5D) at baseline and regular intervals * Have regular follow-up visits with imaging and clinical assessments for up to 36 months to monitor for disease recurrence or progression
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 28 Dec 2025
- Start date
- Feb 2026
- Primary completion date
- Feb 2031
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Diseases
- Childhood cancers
- NCT number
- NCT07328074
What you commit to
- Study type: Observational
- Planned participants: 70
- From Feb 2026 to the primary completion date, Feb 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe systemic comorbidities, such as active infection, poorly controlled diabetes, coagulopathy, bleeding tendency, or ongoing thrombolytic/anticoagulation therapy
- History of organ transplantation (including autologous bone marrow transplantation and peripheral blood stem cell transplantation)
- History of peripheral nervous system disease, significant psychiatric disorder, or central nervous system disease
Lab values
- Positive serum pregnancy test or lactation (females)
Other
- Evidence of extrathoracic metastasis on imaging or pathological examination
- Myasthenia gravis in unstable phase or acute exacerbation
- Currently participating in other clinical trials
Who the study is looking for
- Pathologically confirmed thymic epithelial tumor (TET)
- Imaging evidence of thymic epithelial tumor with pleural dissemination or recurrence, deemed suitable for HITHOC by multidisciplinary thoracic team
- Age ≥16 years and ≤80 years
- American Society of Anesthesiologists (ASA) physical status classification I-II
- Normal major organ function
- No history of other malignancies
- Prior chemotherapy completed \>4 weeks, radiotherapy \>6 weeks, immunotherapy \>6 weeks before enrollment
- No allergy to cisplatin or doxorubicin
- Able to understand the study content and provide informed consent
Age in the registry: 16 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai General Hospital, Department of Thoracic Surgery Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.